CF
VIR icon

Corebridge Financial’s Vir Biotechnology VIR Stock Holding History

Corebridge Financial’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-47,454
Closed -$308K – 2705
2025
Q1 		$308K Sell
47,454
-318
-0.7% -$2.83K ﹤0.01% 1843
2024
Q4 		$351K Sell
47,772
-3,705
-7% -$29.2K ﹤0.01% 1857
2024
Q3 		$386K Sell
51,477
-361
-0.7% -$3.14K ﹤0.01% 1868
2024
Q2 		$461K Buy
+51,838
New +$497K ﹤0.01% 1729

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Corebridge Financial's VIR Position: Q2 2025 in Review

Corebridge Financial sold out of Vir Biotechnology (VIR) in Q2 2025, closing a stake of 47,454 shares — an estimated $308K sold.

Corebridge Financial first reported a position in VIR in Q2 2024 and held it in 4 quarters. The position peaked at $461K in Q2 2024. 213 funds tracked by Wall St. Rank hold VIR as of Q2 2025.

  • Corebridge Financial reported no remaining Vir Biotechnology position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 47,454 Vir Biotechnology shares in Q2 2025, an estimated $308K.
  • Corebridge Financial first reported a position in Vir Biotechnology in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Vir Biotechnology position peaked at $461K in Q2 2024.
  • 213 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.